Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2019 | Pages:
185 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global opioid use disorder market size is expected to reach USD 4.5 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 10.1% over the forecast period. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs. According to the CDC, around 130 Americans die every day due to the opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care. To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use. Further key findings from the report suggest: • Buprenorphine was the largest revenue generating segment in 2018. Its sublingual tablets and branded drug Suboxone are the most widely prescribed drug for OUD • Suboxone is the highest prescribed drug in the OUD market, mostly due to its excellent clinical profile • Sublocade, a buprenorphine product, is estimated to be the largest and fastest growing product over the forecast period, as it is the first long-acting buprenorphine and the first once-monthly product • North America generated the highest revenue in 2018, followed by Europe • Some of the major players in the opioid use disorder market include are Indivior, Alkermes, Titan Pharmaceuticals, Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, and Omeros • The key players are adopting strategies such as mergers and acquisitions, product development, product extension, and regional expansion to increase their market share • In 2018, Orexo AB announced that it obtained the rights to commercialize Zubsolv in all the territories outside the U.S. from its current partner Mundipharma
Table of Contents
Chapter 1. Methodology and Scope
1.1.Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR's internal database
1.3.3. Secondary sources & Third party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Opioid Use Disorder Market Variables, Trends & Scope
3.1. Penetration & Growth Prospect Mapping
3.2. Regulatory Framework
3.2.1. Reimbursement framework
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Rising opioid epidemic
3.3.1.2. Growing government initiatives to combat the crisis
3.3.2. Market restraint analysis
3.3.2.1. Copmlex reimbursement structure
3.4. Opioid Use Disorder Market Analysis Tools
3.4.1. Industry analysis - Porter's
3.4.1.1. Supplier power (Moderate due to requirement of high-quality raw materials)
3.4.1.2. Buyer power (Moderate due to limited number of established providers)
3.4.1.3. Substitution threat (Moderate due to clinical development of new compounds)
3.4.1.4. New entrants' threat (High as the market is underserved)
3.4.1.5. Competitive rivalry (Moderate due to presence of few key players)
3.4.2. PESTEL analysis
3.4.2.1. Political landscape
3.4.2.2. Environmental landscape
3.4.2.3. Social landscape
3.4.2.4. Technology landscape
3.4.2.5. Legal landscape
3.4.3. Major deals & strategic alliances analysis
3.4.3.1. Joint ventures
3.4.3.2. Mergers & acquisitions
Chapter 4. Opioid Use Disorder Market - Competitive Analysis
4.1. Recent Developments & Impact Analysis, by Key Market Participants
4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
4.3. Public Companies
4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.3.2. Company market share
4.3.3. Synergy analysis: Major deals & strategic alliances
4.4. Private Companies
4.4.1. List of key emerging companies
4.4.2. Regional network map
4.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
Chapter 5. Opioid Use Disorder Market: Drug Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Drug Market Share Analysis, 2018 & 2026
5.3. Opioid Use Disorder Market, by Drug, 2015 to 2026
5.4. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
5.4.1. Buprenorphine
5.4.1.1 Buprenorphine market, 2015 - 2026 (USD Million)
5.4.1.2 Bunavail
5.4.1.2.1 Bunavail market, 2015 - 2026 (USD Million)
5.4.1.3 Sublocade
5.4.1.3.1 Sublocade market, 2015 - 2026 (USD Million)
5.4.1.4 Suboxone
5.4.1.4.1 Suboxone market, 2015 - 2026 (USD Million)
5.4.1.5 Zubsolv
5.4.1.5.1 Sublocade market, 2015 - 2026 (USD Million)
5.4.1.6 Others
5.4.1.6.1 Others market, 2015 - 2026 (USD Million)
5.4.2. Methadone
5.4.2.1 Methadone market, 2015 - 2026 (USD Million)
5.4.3. Naltrexone
5.4.3.1 Naltrexone market, 2015 - 2026 (USD Million)
Chapter 6 Opioid Use Disorder Market: Regional Estimates & Trend Analysis, by Drug
6.1 Opioid Use Disorder Market: Regional Movement Analysis, 2018 & 2026
6.2 Opioid Use Disorder Market: Leading Players, 2018:
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America and Middle East & Africa
6.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America and Middle East & Africa
6.4 North America
6.4.1 North America market, 2015 - 2026 (USD Million)
6.4.2 U.S.
6.4.2.1 U.S. market, 2015 - 2026 (USD Million)
6.4.3 Canada
6.4.3.1 Canada market, 2015 - 2026 (USD Million)
6.5. Europe
6.5.1 Europe market, 2015 - 2026 (USD Million)
6.5.2 UK
6.5.2.1 UK market, 2015 - 2026 (USD Million)
6.5.3 Germany
6.5.3.1 Germany market, 2015 - 2026 (USD Million)
6.5.4 France
6.5.4.1 France market, 2015 - 2026 (USD Million)
6.5.5 Italy
6.5.5.1 Italy market, 2015 - 2026 (USD Million)
6.5.6 Spain
6.5.6.1 Spain market, 2015 - 2026 (USD Million)
6.6 Asia Pacific
6.6.1 Asia Pacific market, 2015 - 2026 (USD Million)
6.6.2 Australia
6.6.2.1 Australia market, 2015 - 2026 (USD Million)
6.6.3 China
6.6.3.1 China market, 2015 - 2026 (USD Million)
6.7 Latin America and Middle East & Africa
6.7.1 and Middle East & Africa market, 2015 - 2026 (USD Million)
6.7.2 Brazil
6.7.2.1 Brazil market, 2015 - 2026 (USD Million)
6.7.3 South Africa
6.7.3.1 South Africa market, 2015 - 2026 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Heat Map Analysis of Private Companies
7.2.1 Company size
7.2.2 Distribution network
7.2.3 Product portfolio
7.2.4 Segment coverage
7.2.5 Geographic presence
7.2.6 Collaborations
7.2.7 Conclusion
7.3 Indivior PLC
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 BioDelivery Sciences International, Inc.
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 Alkermes, Inc.
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 Orexo US, Inc.
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic initiatives
7.7 Titan Pharmaceuticals, Inc.
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Product benchmarking
7.7.4 Strategic initiatives
7.8 Omeros Corporation
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
7.9 Camurus
7.9.1 Company overview
7.9.2 Financial performance
7.9.3 Product benchmarking
7.9.4 Strategic initiatives
7.10 Hikma Pharmaceuticals PLC
7.10.1 Company overview
7.10.2 Financial performance
7.10.3 Product benchmarking
7.10.4 Strategic initiatives
List of Tables TABLE 1 Country share estimation TABLE 2 North America opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 3 North America buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 4 U.S. opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 5 U.S. buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 6 Canada opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 7 Canada buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 8 Europe opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 9 Europe buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 10 UK opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 11 UK buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 12 Germany opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 13 Germany buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 14 France opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 15 France buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 16 Spain opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 17 Spain buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 18 Italy opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 19 Italy buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 20 Asia Pacific opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 21 Asia Pacific buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 22 China opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 23 China buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 24 Australia opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 25 Australia buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 26 Latin America and Middle East & Africa opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 27 Latin America and Middle East & Africa buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 28 Brazil opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 29 Brazil buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million) TABLE 30 South Africa opioid use disorder market estimates and forecasts, by drug, 2015 - 2026 (USD Million) TABLE 31 South Africa buprenorphine market estimates and forecasts, by product, 2015 - 2026 (USD Million)
List of Figures FIG. 1 Market research process FIG. 2 Information procurement FIG. 3 Market summary, 2018 FIG. 4 Market trends & outlook FIG. 5 Market segmentation & scope FIG. 6 Market driver relevance analysis (Current & future impact) FIG. 7 Market restrain relevance analysis (Current & future impact) FIG. 8 Penetration & growth prospect mapping FIG. 9 SWOT analysis, by factor (political & legal, economic and technological) FIG. 10 Porter's five forces analysis FIG. 11 Opioid use disorder market drug outlook key takeaways FIG. 12 Opioid use disorder market: Drug movement analysis FIG. 13 Global Buprenorphine market, 2015 - 2026 (USD Million) FIG. 14 Global Bunavail market, 2015 - 2026 (USD Million) FIG. 15 Global Sublocade market, 2015 - 2026 (USD Million) FIG. 16 Global Suboxone market, 2015 - 2026 (USD Million) FIG. 17 Global Zubsolv market, 2015 - 2026 (USD Million) FIG. 18 Global others market, 2015 - 2026 (USD Million) FIG. 19 Global Methadone market, 2015 - 2026 (USD Million) FIG. 20 Global Naltrexone market, 2015 - 2026 (USD Million) FIG. 21 Regional market place: Key takeaways, 2018 FIG. 22 Regional outlook, 2018 & 2026 FIG. 23 North America opioid use disorder market, 2015 - 2026 (USD Million) FIG. 24 U.S. opioid use disorder market, 2015 - 2026 (USD Million) FIG. 25 Canada opioid use disorder market, 2015 - 2026 (USD Million) FIG. 26 Europe opioid use disorder market, 2015 - 2026 (USD Million) FIG. 27 UK opioid use disorder market, 2015 - 2026 (USD Million) FIG. 28 Germany opioid use disorder market, 2015 - 2026 (USD Million) FIG. 29 France opioid use disorder market, 2015 - 2026 (USD Million) FIG. 30 Spain opioid use disorder market, 2015 - 2026 (USD Million) FIG. 31 Italy opioid use disorder market, 2015 - 2026 (USD Million) FIG. 32 Asia Pacific opioid use disorder market, 2015 - 2026 (USD Million) FIG. 33 Australia opioid use disorder market, 2015 - 2026 (USD Million) FIG. 34 China opioid use disorder market, 2015 - 2026 (USD Million) FIG. 35 Latin America and Middle East & Africa opioid use disorder market, 2015 - 2026 (USD Million) FIG. 36 Brazil opioid use disorder market, 2015 - 2026 (USD Million) FIG. 37 South Africa opioid use disorder market, 2015 - 2026 (USD Million) FIG. 38 Strategy framework FIG. 39 Participant categorization
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
